Cargando…

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy

BACKGROUND: Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome relationship in obstructive hypertrophic cardiomyopath...

Descripción completa

Detalles Bibliográficos
Autores principales: Altibi, Ahmed M., Ghanem, Fares, Zhao, Yuanzi, Elman, Miriam, Cigarroa, Joaquin, Nazer, Babak, Song, Howard K., Masri, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227305/
https://www.ncbi.nlm.nih.gov/pubmed/37183831
http://dx.doi.org/10.1161/JAHA.122.028693
_version_ 1785050741624274944
author Altibi, Ahmed M.
Ghanem, Fares
Zhao, Yuanzi
Elman, Miriam
Cigarroa, Joaquin
Nazer, Babak
Song, Howard K.
Masri, Ahmad
author_facet Altibi, Ahmed M.
Ghanem, Fares
Zhao, Yuanzi
Elman, Miriam
Cigarroa, Joaquin
Nazer, Babak
Song, Howard K.
Masri, Ahmad
author_sort Altibi, Ahmed M.
collection PubMed
description BACKGROUND: Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome relationship in obstructive hypertrophic cardiomyopathy. METHODS AND RESULTS: All septal reduction therapy admissions between 2010 to 2019 in the United States were analyzed using the National Readmission Databases. Hospitals were stratified into tertiles of low‐, medium‐, and high‐volume based on annualized procedural volume of alcohol septal ablation and SM. Of 19 007 patients with obstructive hypertrophic cardiomyopathy who underwent septal reduction therapy, 12 065 (63%) had SM. Two‐thirds of hospitals performed ≤5 SM or alcohol septal ablation annually. In all SM encounters, 482 patients (4.0%) died in‐hospital post‐SM. In‐hospital mortality was <1% in 1505 (88.4%) hospitals, 1% to 10% in 30 (1.8%) hospitals, and ≥10% in 167 (9.8%) hospitals. There were 63 (3.7%) hospitals (averaging 2.2 SM cases/year) with 100% in‐hospital mortality. Post‐SM (in low‐, medium‐, and high‐volume centers, respectively), in‐hospital mortality (5.7% versus 3.9% versus 2.4%, P=0.003; adjusted odds ratio [aOR], 2.86 [95% CI, 1.70–4.80], P=0.001), adverse in‐hospital events (21.30% versus 18.0% versus 12.6%, P=0.001; aOR, 1.88 [95% CI, 1.45–2.43], P=0.001), and 30‐day readmission (17.1% versus 12.9% versus 9.7%, P=0.001; adjusted hazard ratio, 1.53 [95% CI, 1.27–1.96], P=0.001) were significantly higher in low‐ versus high‐volume hospitals. For alcohol septal ablation, the incidence of in‐hospital death and all other outcomes did not differ by hospital volume. CONCLUSIONS: In‐hospital SM mortality was 4% with an inverse volume‐mortality relationship. Mortality post‐alcohol septal ablation was similar across all volume tertiles. Morbidity associated with SM was substantial across all volume tertiles.
format Online
Article
Text
id pubmed-10227305
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102273052023-05-31 Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Altibi, Ahmed M. Ghanem, Fares Zhao, Yuanzi Elman, Miriam Cigarroa, Joaquin Nazer, Babak Song, Howard K. Masri, Ahmad J Am Heart Assoc Original Research BACKGROUND: Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome relationship in obstructive hypertrophic cardiomyopathy. METHODS AND RESULTS: All septal reduction therapy admissions between 2010 to 2019 in the United States were analyzed using the National Readmission Databases. Hospitals were stratified into tertiles of low‐, medium‐, and high‐volume based on annualized procedural volume of alcohol septal ablation and SM. Of 19 007 patients with obstructive hypertrophic cardiomyopathy who underwent septal reduction therapy, 12 065 (63%) had SM. Two‐thirds of hospitals performed ≤5 SM or alcohol septal ablation annually. In all SM encounters, 482 patients (4.0%) died in‐hospital post‐SM. In‐hospital mortality was <1% in 1505 (88.4%) hospitals, 1% to 10% in 30 (1.8%) hospitals, and ≥10% in 167 (9.8%) hospitals. There were 63 (3.7%) hospitals (averaging 2.2 SM cases/year) with 100% in‐hospital mortality. Post‐SM (in low‐, medium‐, and high‐volume centers, respectively), in‐hospital mortality (5.7% versus 3.9% versus 2.4%, P=0.003; adjusted odds ratio [aOR], 2.86 [95% CI, 1.70–4.80], P=0.001), adverse in‐hospital events (21.30% versus 18.0% versus 12.6%, P=0.001; aOR, 1.88 [95% CI, 1.45–2.43], P=0.001), and 30‐day readmission (17.1% versus 12.9% versus 9.7%, P=0.001; adjusted hazard ratio, 1.53 [95% CI, 1.27–1.96], P=0.001) were significantly higher in low‐ versus high‐volume hospitals. For alcohol septal ablation, the incidence of in‐hospital death and all other outcomes did not differ by hospital volume. CONCLUSIONS: In‐hospital SM mortality was 4% with an inverse volume‐mortality relationship. Mortality post‐alcohol septal ablation was similar across all volume tertiles. Morbidity associated with SM was substantial across all volume tertiles. John Wiley and Sons Inc. 2023-05-15 /pmc/articles/PMC10227305/ /pubmed/37183831 http://dx.doi.org/10.1161/JAHA.122.028693 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Altibi, Ahmed M.
Ghanem, Fares
Zhao, Yuanzi
Elman, Miriam
Cigarroa, Joaquin
Nazer, Babak
Song, Howard K.
Masri, Ahmad
Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
title Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
title_full Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
title_fullStr Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
title_full_unstemmed Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
title_short Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
title_sort hospital procedural volume and clinical outcomes following septal reduction therapy in obstructive hypertrophic cardiomyopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227305/
https://www.ncbi.nlm.nih.gov/pubmed/37183831
http://dx.doi.org/10.1161/JAHA.122.028693
work_keys_str_mv AT altibiahmedm hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT ghanemfares hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT zhaoyuanzi hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT elmanmiriam hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT cigarroajoaquin hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT nazerbabak hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT songhowardk hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy
AT masriahmad hospitalproceduralvolumeandclinicaloutcomesfollowingseptalreductiontherapyinobstructivehypertrophiccardiomyopathy